BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Trading 08-07 13:15:15 EDT

345.72

+15.92

+4.83%

High349.88	Low341.88	Vol354.40K
Open345.47	D1 Closing329.80	Amplitude2.43%
Mkt Cap39.41B	Tradable Cap29.63B	Total Shares114.00M
T/O122.50M	T/O Rate0.41%	Tradable Shares85.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":345.7203,"timestamp":1786122911506,"preClose":329.8,"halted":0,"volume":354402,"delay":0,"changeRate":0.04827258944815038,"floatShares":85693500,"shares":113999999,"eps":5.589356,"marketStatus":"Trading","change":15.9203,"latestTime":"08-07 13:15:15 EDT","open":345.47,"high":349.88,"low":341.875,"amount":122504023.56006001,"amplitude":0.024272,"askPrice":346.22,"askSize":80,"bidPrice":345.72,"bidSize":46,"shortable":3,"etf":0,"ttmEps":5.589356,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786132800000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":329.8,"preHourTrading":{"tag":"盘前","latestPrice":344.42,"preClose":329.8,"latestTime":"09:27 EDT","volume":16913,"amount":5635585.29651,"timestamp":1786109269511,"change":14.62,"changeRate":0.04433,"amplitude":0.03769},"postHourTrading":{"tag":"盘后","latestPrice":330,"preClose":329.8,"latestTime":"19:34 EDT","volume":17149,"amount":5655753,"timestamp":1786059249833,"change":0.2,"changeRate":0.000606,"amplitude":0.000606},"volumeRatio":1.746227,"impliedVol":0.3639,"impliedVolPercentile":0.0478},"requestUrl":"/m/hq/s/ONC/tweets","defaultTab":"tweets","newsList":[{"id":"1106596419","title":"Movement Alert｜BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.49% in Regular Trading, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=1106596419","media":"Market Focus","labels":["dataReport"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1106596419?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:32","pubTimestamp":1786109532,"startTime":"0","endTime":"0","summary":"On August 7, BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS rose 5.49% in regular trading, trading at $347.675/share, with turnover of $26.0053 million.On the news front, the company reported Q2 global...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"ONC Rises, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169077073","title":"BEONE MEDICINES: Approximately 95% of Pancreatic Cancer Cases Show KRAS Mutation, Around 20% Exhibit MTAP Deletion, Enabling Easy Identification of Overlapping Patient Groups","url":"https://stock-news.laohu8.com/highlight/detail?id=1169077073","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169077073?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:21","pubTimestamp":1786112482,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES stated during a research briefing that both MTAP deletions and KRAS mutations are high-frequency molecular events in human tumors, theoretically offering numerous opportunities for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK1588","BK1583","LU1251922891.USD","BK4139","BK4526","BK4588","LU0588546209.SGD","LU1770034418.SGD","BK4585","KURE","BK0239","ONC","LU1719994722.HKD","BK1500","BK1161","688235","06160","LU0307460666.USD","LU1303224171.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136694467","title":"BEONE MEDICINES Reports BRUKINSA Captures Over Half of New CLL/SLL Patient Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1136694467","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136694467?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:53","pubTimestamp":1786110785,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES disclosed during a recent investor briefing that, while different data sources may show slight variations in measuring new patient market share in the United States, BRUKINSA has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK4139","BK4526","BK4585","BK1161","BK4588","ONC","LU2328871848.SGD","LU1303224171.USD","LU1719994722.HKD","BK0239","BK1583","LU0588546209.SGD","06160","LU1251922891.USD","BK1500","KURE","688235","LU0307460666.USD","LU1969619763.USD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120299531","title":"Beigene's GPC3x4-1BB Candidate Moves From Phase 1 to a Potential Pivotal Phase 2 Study in About 19 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1120299531","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120299531?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:51","pubTimestamp":1786110707,"startTime":"0","endTime":"0","summary":"Beigene revealed during a recent investor call that its GPC3x4-1BB bispecific antibody transitioned from first-in-human studies to the initiation of a potential registrational Phase 2 trial in...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4526","ONC","LU0307460666.USD","LU1303224171.USD","LU0588546209.SGD","LU1719994722.HKD","BK1500","BK0239","BK1583","688235","BK1588","LU2328871848.SGD","LU1969619763.USD","KURE","LU1770034418.SGD","06160","BK4585","LU1251922891.USD","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143385668","title":"BEONE MEDICINES Halts Initial KRAS Inhibitor Project but Remains Active in RAS Field","url":"https://stock-news.laohu8.com/highlight/detail?id=1143385668","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143385668?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:51","pubTimestamp":1786110683,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES has revealed that it has discontinued development of its original Pan-KRAS inhibitor known as BGB-53038. However, the company has confirmed that it is not withdrawing from the broader...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","BK4526","BK4588","LU2328871848.SGD","BK4139","LU0307460666.USD","BK4585","BGB","BK1161","BK1583","688235","LU1969619763.USD","LU0588546209.SGD","BK0239","KURE","LU1770034418.SGD","BK1588","LU1719994722.HKD","LU1303224171.USD","LU1251922891.USD","ONC","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114647524","title":"BEONE MEDICINES Plans to Unveil Preliminary CEA ADC Findings for Non-Small Cell Lung Cancer, Including Both Squamous and Non-Squamous Cases","url":"https://stock-news.laohu8.com/highlight/detail?id=1114647524","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114647524?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:50","pubTimestamp":1786110636,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES (06160.HK) announced during a research briefing that it intends to publish early-stage data on its CEA-targeting antibody-drug conjugate (ADC) for non-small cell lung cancer (NSCLC),...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770034418.SGD","LU1719994722.HKD","06160","BK4585","LU1251922891.USD","BK1588","BK4588","BK4080","LU2328871848.SGD","BK4231","LU0588546209.SGD","ONC","BK4526","BK1500","LU0307460666.USD","BK0239","NETL","LU1303224171.USD","ADC","KURE","BK1583","BK4139","LU1969619763.USD","688235","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183635165","title":"Movement Alert｜BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.48% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=1183635165","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183635165?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:03","pubTimestamp":1786089813,"startTime":"0","endTime":"0","summary":"On August 7, BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS rose 5.48% in pre-market trading, trading at $345.87/share, with turnover of $719,300.On the news front, the company reported Q2 results that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"ONC Rises, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162476713","title":"Movement Alert｜BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.16% Overnight, Q2 Earnings Beat Expectations as Multiple Institutions Raise Target Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=1162476713","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162476713?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:19","pubTimestamp":1786083551,"startTime":"0","endTime":"0","summary":"On August 7, BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS rose 5.16% overnight, trading at $346.83/share, with turnover of $4.8164 million. The rally was driven by the company's Q2 earnings...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175866516","title":"CLSA Maintains Outperform Rating on BEONE MEDICINES, Raises Price Target to HK$321.70","url":"https://stock-news.laohu8.com/highlight/detail?id=1175866516","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175866516?lang=en_us&edition=fundamental","pubTime":"2026-08-07 14:10","pubTimestamp":1786083040,"startTime":"0","endTime":"0","summary":"CLSA issued a research report raising the target price for BEONE MEDICINES (06160) from HK$291.9 to HK$321.7. The firm also increased the U.S. stock target for BEIGENE LTD SPON ADS EACH REPR 13 ORD...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","EWH","688235","LU1251922891.USD","KURE","LU0307460666.USD","BK1500","LU2328871848.SGD","BK1588","BK1583","BK4588","LU0588546209.SGD","BK4139","LU1303224171.USD","06160","BK4585","LU1969619763.USD","LU1770034418.SGD","ONC","LU1719994722.HKD","BK4526","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106523435","title":"BEONE MEDICINES Surges Over 4% Intraday as UOB Kay Hian Raises Target Price to HK$265","url":"https://stock-news.laohu8.com/highlight/detail?id=1106523435","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106523435?lang=en_us&edition=fundamental","pubTime":"2026-08-07 12:00","pubTimestamp":1786075228,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES (06160) saw its shares climb more than 4% during Tuesday's trading session following the release of its quarterly results. As of the latest update, the stock was up 2.46% to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EWH","LU1251922891.USD","BK1588","BK1161","688235","LU1719994722.HKD","LU0588546209.SGD","LU0307460666.USD","LU1969619763.USD","LU1770034418.SGD","06160","KURE","BK1583","BK4526","BK0239","LU1303224171.USD","BK4585","LU2328871848.SGD","ONC","BK1500","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657696311","title":"BeOne Medicines (ONC) Earnings Beat And Higher Guidance Leave Valuation In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2657696311","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657696311?lang=en_us&edition=fundamental","pubTime":"2026-08-07 11:43","pubTimestamp":1786074192,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) stock is in focus after the company reported second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance on 5 August 2026.\nSee our latest analysis for BeOne Medicines.\nThe latest earnings surprise and higher 2026 guidance appear to be feeding into BeOne Medicines' momentum, with a 30-day share price return of 6.75% and a 1-year total shareholder return of 10.56%. The 3-year total shareholder return of 66.63% reflects a stronger long...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-earnings-beat-and-higher-guidance-leave","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-earnings-beat-and-higher-guidance-leave","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157467291","title":"Hong Kong Stock Moves: BEONE MEDICINES Surges Nearly 4% After Earnings, Adjusted Net Profit Up 111% YoY in First Half, Solid Tumor Progress Noted","url":"https://stock-news.laohu8.com/highlight/detail?id=1157467291","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157467291?lang=en_us&edition=fundamental","pubTime":"2026-08-07 10:04","pubTimestamp":1786068259,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES (06160) shares rose nearly 4% following its earnings release, trading up 3.66% at HK$206.8 as of press time, with a turnover of HK$362 million.On August 6, the company reported its...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","688235","LU1251922891.USD","KURE","LU0307460666.USD","BK1500","LU2328871848.SGD","BK1588","BK1583","BK4588","LU0588546209.SGD","BK4139","LU1303224171.USD","06160","KCAI","BK4585","LU1969619763.USD","LU1770034418.SGD","ONC","VXUS","LU1719994722.HKD","BK4526","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657965623","title":"BeOne Medicines Shares Trading At Discount To Fair Value, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2657965623","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657965623?lang=en_us&edition=fundamental","pubTime":"2026-08-07 00:41","pubTimestamp":1786034463,"startTime":"0","endTime":"0","summary":"BeOne Medicines  shares are trading at a discount to the company's fair value, and investors are overindexing on risks to the Brukinsa franchise, RBC said in a note.The brokerage said the investors are \"not ascribing credit to the solid tumor work - and we would be buyers into 2H26.\"RBC said it likes the company's strong commercial performance with beats across the board on revenue and EPS as evidence of sustainable heme-onc leadership.The company also said Brukinsa continues to grow, with additional label expansion opportunities supporting long-term picture, adding that it looked very impressive, with $1.25 billion in revenue.RBC said that compared with its estimate of $1.23 billion and the Street estimate of $1.20 billion, driven by new patients, improving duration of therapy, and better adherence.RBC maintained a an outperform rating and lowered price target to $450 from $451.Price: 326.88, Change: -0.65, Percent Change: -0.20","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","MDCO","BK4139","BK4585","ONC","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657249639","title":"Beone Medicines : Leerink Partners Raises Target Price to $387 from $377","url":"https://stock-news.laohu8.com/highlight/detail?id=2657249639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657249639?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:23","pubTimestamp":1786019014,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4431SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","688235","BK4526","BK4588","BK0239","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657689351","title":"Barclays Remains a Buy on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657689351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657689351?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:57","pubTimestamp":1786006621,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Buy rating on BeOne Medicines today and set a price target of $407.00. According to TipRanks, Darout is ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4585","BK4526","BK4588","BK4139","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657502079","title":"Beone Medicines : TD Cowen Raises Target Price to $454 from $424","url":"https://stock-news.laohu8.com/highlight/detail?id=2657502079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657502079?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:25","pubTimestamp":1785997523,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4430PZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688235","BK4139","BK4526","BK4588","BK0239","ONC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143571336","title":"Interim Net Profit Surges 627%, Full-Year Revenue Guidance Raised: Beone Medicines Rebounds on Hong Kong Exchange, Huabao's Innovative Drug ETF Sees Premium Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1143571336","media":"Deep News","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143571336?lang=en_us&edition=fundamental","pubTime":"2026-08-06 11:30","pubTimestamp":1785987038,"startTime":"0","endTime":"0","summary":"Beone Medicines (06160.HK) has delivered a standout financial report, reinforcing the strong momentum in the innovative drug sector. Following the impressive results from CXO leader WuXi AppTec, the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK1500","LU1251922891.USD","LU1770034418.SGD","BK1161","VXUS","LU0307460666.USD","BK0239","BK4139","LU1719994722.HKD","BK4588","LU1303224171.USD","KCAI","688235","06160","520880","BK4585","BK1583","159316","ONC","LU1969619763.USD","KURE","LU0588546209.SGD","BK4526","BK1588","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174657246","title":"Hong Kong Stock Exchange News Highlights: Beone Medicines Sees 111% Surge in Adjusted Net Profit for First Half of the Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1174657246","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174657246?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:11","pubTimestamp":1785978684,"startTime":"0","endTime":"0","summary":"Major DevelopmentsCSPC Pharmaceutical Group (01093) has signed a joint venture agreement with AstraZeneca to deepen their strategic collaboration through the establishment of a new company.YouRan...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU0084288322.USD","LU0501845795.SGD","LU0082770016.USD","LU0417516738.SGD","LU1188198961.HKD","00220","LU1981816686.USD","09858","LU0675040207.SGD","LU0449509016.USD","LU1226287529.USD","LU1303224171.USD","LU1323998911.USD","LU1813983027.USD","LU1328277881.USD","LU0441854154.USD","LU0650527681.SGD","LU1282648689.USD","LU2328871848.SGD","IE0032431581.USD","IE00BQJZWZ67.USD","LU0499858602.USD","LU0307460666.USD","LU0605514214.HKD","IE00B5MMRT66.SGD","LU1226287792.SGD","LU0348825331.USD","LU0320764599.SGD","BK4526","LU2152927971.USD","LU0531971595.HKD","BK1523","KCAI","LU0314109678.HKD","LU0327786744.USD","LU0348827113.USD","LU0054450605.USD","LU0072913022.USD","LU0620787316.HKD","BK4585","LU0210526637.USD","LU1152091754.HKD","LU2476274308.USD","XIACY","LU0588546209.SGD","LU0880133367.SGD","LU0823040885.USD","BK1502","BK1521","LU2399975544.HKD","IE00BZ08YT58.USD","LU0348814723.USD","IE00B031HY20.USD","LU1226288170.HKD","01093","BK1588","HK0000286598.CNH","LU0326950275.SGD","IE00BZ08YR35.GBP","LU0117841782.USD","LU1993786604.SGD","LU1152091168.USD","LU2097828631.EUR","LU0254981946.USD","ONC","LU0823426308.USD","LU1951186391.HKD","LU1969619763.USD","LU0164865239.USD","LU0708995583.HKD","LU1251922891.USD","SG9999002463.SGD","LU0348816934.USD","LU0348735423.USD","LU2097828557.USD","LU1770034418.SGD","IE00B0169L03.USD","LU0823426480.USD","LU0823039010.USD","LU1719994722.HKD","LU1961090484.USD","LU2257852520.SGD","LU2294711473.HKD","LU0235996351.USD","LU2097828805.USD","HXXD.SI","LU1807302812.USD","LU2778985437.USD","LU0918141887.USD","LU0039217434.USD","BK1549","IE00BWDBJ730.SGD","LU0463099449.HKD","LU0169518387.USD","LU0211977185.USD","LU0231483743.USD","LU1720050803.USD","IE00B3M56506.USD","LU1105468828.SGD","IE00B543WZ88.USD","BK1615","LU1880383440.USD","BK1583","HK0000165453.HKD","BK1161","MIUmain","LU0456846285.SGD","LU0067412154.USD","BK1500","688235","LU0244354667.USD","LU0164880469.USD","LU0082770016.SGD","LU0140636845.USD","IE0008368742.USD","SG9999003461.SGD","BK1193","LU0164939612.USD","LU0531970944.HKD","BK0239","BK1618","IE00BZ08YS42.EUR","BK1607","LU0823038988.USD","LU0143863198.USD","LU0143863784.USD","LU0359201612.USD","LU0561508036.HKD","LU0164872284.USD","06160","LU0823413587.USD","LU2097828474.EUR","LU1880383366.USD","BK1212","LU0449515922.USD","LU2476274720.SGD","LU1226288253.USD","LU0797268264.HKD","LU1794554557.SGD","BK4588","LU2226246903.HKD","LU1868838027.USD","LU0871576103.HKD","IE0034224299.USD","BK1515","LU1008478684.HKD","LU0052750758.USD","LU2039709279.SGD","BK1506","IE00B19Z5X02.USD","LU0359202008.SGD","LU0051755006.USD","LU2097828714.EUR","LU0823041008.USD","LU0214875030.USD","LU2087589342.USD","BK1191","DRGN","LU0823413660.USD","SG9999004220.SGD","VXUS","LU1770036033.HKD","LU0499858438.USD","LU1808992512.USD","SG9999001093.SGD","LU0611395673.USD","LU0417516902.SGD","LU0640798160.USD","LU0359201885.HKD","LU0315179316.USD","LU0594300179.USD","LU1115378108.SGD","IE0008369823.USD","KURE","LU0700851271.USD","LU1960683339.HKD","BK1587","LU1956131251.USD","BK1575","LU0823397103.USD","BK1610","BK1237","LU1226287875.USD","LU0540923850.HKD","LU1023057109.AUD","LU0823397285.USD","LU1868837565.USD","LU1481107354.HKD","LU0345776255.USD","BK4139","01810","LU0634319403.HKD","LU0456827905.SGD","81810","LU0345775950.USD","LU0594300419.USD","LU0572944931.SGD","LU0918141705.HKD","LU0149721374.USD","LU0593848301.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130410758","title":"Livermore Index of Leading Chinese Stocks Edges Up 0.1% at Market Open","url":"https://stock-news.laohu8.com/highlight/detail?id=1130410758","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130410758?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:41","pubTimestamp":1785940900,"startTime":"0","endTime":"0","summary":"Silvercorp Metals leads gainers with a 6.86% surge at the opening bell on August 5, as the Livermore index tracking top Chinese concept stocks rose 0.1%.Other notable performers include BEONE...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","MLCO","688235","BK4139","BK4585","BK4166","BK4505","06160","BK4588","SVM","SLVX","BK4210","FINV","ONC","BK4526","BK4150","SLVR","AS","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657285485","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR), American Well (AMWL) and BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657285485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657285485?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:00","pubTimestamp":1785938430,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cencora (COR), American Well (AMWL) and BeOne Medicines (ONC). Ce...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cencora-cor-american-well-amwl-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cencora-cor-american-well-amwl-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1084165304.USD","AMWL","XBI","BK4139","LU0128526141.USD","LU1119994496.HKD","SG9999004303.SGD","BK4175","COR","BK4529","LU2237957811.SGD","BK4084","XLV","BK4526","BK4585","LU1430594728.SGD","BK4137","LU2237957902.USD","LU1814569148.SGD","ONC","LABU","LU1261432733.SGD","LU0289739699.SGD","LU1585245621.USD","BK4167","MDCO","BK4588","LU0058720904.USD","SGXZ23171101.USD","BK4581","HCSG","LU0029874061.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.024},{"period":"1month","weight":0.0675},{"period":"3month","weight":0.0566},{"period":"6month","weight":-0.0682},{"period":"1year","weight":0.1048},{"period":"ytd","weight":0.0855}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.02929},{"month":4,"riseRate":0.363636,"avgChangeRate":0.018832},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.019621},{"month":6,"riseRate":0.454545,"avgChangeRate":0.010403},{"month":7,"riseRate":0.818182,"avgChangeRate":0.143728},{"month":8,"riseRate":0.636364,"avgChangeRate":0.035059},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","securityTypeName":"DR","adrRate":"1:13"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction